Dr Reddy’s Earnings Plunge On German Unit Charge, Increased Generic Competition
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Dr Reddy's Laboratories, India's second-biggest drugmaker, said third quarter earnings and revenues plunged on lower-than-expected earnings in Germany and increased competition as it changes its mix of generic drug products
You may also be interested in...
Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry
MUMBAI - India's second largest drug maker Dr. Reddy's Laboratories posted a 26 percent drop in quarterly profit partly due to pricing pressures in the generics business
Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry
MUMBAI - India's second largest drug maker Dr. Reddy's Laboratories posted a 26 percent drop in quarterly profit partly due to pricing pressures in the generics business
Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability
NEW DELHI - India's second biggest generic drug maker said it expects revenue growth of 25 percent in the financial year started April and gross margins of 50 percent led by improved cost control at its German betapharm unit and growing revenues from custom manufacturing and active pharmaceutical ingredient sales after earnings below expectations for the fourth quarter ended March